Results 61 to 70 of about 297,195 (347)

Metachronous Intraductal Papillary Neoplasm of the Bile Duct and Intraductal Papillary Mucinous Neoplasm of the Pancreas in a Patient Diagnosed With Mucinous Adenocarcinoma. [PDF]

, 2019
Intraductal papillary neoplasm of the bile duct (IPNB) is a rare biliary tumor, which shares some radiologic and histologic similarities with pancreatic intraductal papillary mucinous neoplasm (IPMN).
Brennan, Gregory T, Lee, John G
core   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Solid Pseudopapillary Neoplasms of the Pancreas: A Report of Two Cases

Case Reports in Medicine, 2014
Solid pseudopapillary neoplasms of the pancreas are uncommon, accounting for only 1-2% of all pancreatic neoplasms. These tumors are being detected at an increased rate, probably due to the increased awareness and the liberal use of imaging.
Dilip Dan, Rakesh Rambally, Shamir O. Cawich, Ravi Maharaj, Vijay Naraynsingh   +4 more
doaj   +1 more source

Pancreatic neuroendocrine tumor with complete replacement of the pancreas by serous cystic neoplasms in a patient with von Hippel-Lindau disease: a case report

Surgical Case Reports, 2017
Background von Hippel-Lindau disease is a dominantly inherited multi-system syndrome with neoplastic hallmarks. Pancreatic lesions associated with von Hippel-Lindau include serous cystic neoplasms, simple cysts, and neuroendocrine tumors. The combination
Shimpei Maeda, Fuyuhiko Motoi, Shuhei Oana, Kyohei Ariake, Masamichi Mizuma, Takanori Morikawa, Hiroki Hayashi, Kei Nakagawa, Takashi Kamei, Takeshi Naitoh, Michiaki Unno   +10 more
doaj   +1 more source

Pancreatic cysts suspected to be branch duct intraductal papillary mucinous neoplasm without concerning features have low risk for development of pancreatic cancer. [PDF]

, 2015
BackgroundThe risk of developing pancreatic cancer is uncertain in patients with clinically suspected branch duct intraductal papillary mucinous neoplasm (BD-IPMN) based on the "high-risk stigmata" or "worrisome features" criteria proposed in the 2012 ...
Fehmi, Syed A, Giap, Andrew Q, Gonzalez, Ingrid, Hunt, Gordon C, Krinsky, Mary L, Kwong, Wilson T, Lawson, Robert D, Savides, Thomas J, Slezak, Jeff, Tang, Raymond S   +9 more
core   +1 more source

Serous cystic neoplasm of the pancreas: A multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas) [PDF]

, 2015
OBJECTIVES: Serous cystic neoplasm (SCN) is a cystic neoplasm of the pancreas whose natural history is poorly known. The purpose of the study was to attempt to describe the natural history of SCN, including the specific mortality.
Aguero Garcete, G., Angiolini, M. R., Araujo Acuna, I., Arcidiacono, P. G., Balzano, G., Bassi, C., Bernier, B., Bissolati, M., Bolado, F., Brugge, W., Campos, V., Casadei, R., Choi, H. J., Concepcion Martin, M., Conwell, D., Crippa, S., De Angelis, C. G., Del Chiaro, M., Delhaye, M., Faccinetto, A., Falconi, M., Fern\ue1ndez Del Castillo, C., Fontana, M., Frigerio, I., Frulloni, L., Gill, R. S., Girelli, R., Gomatos, I., Ha, Y., Hirai, I., Hruban, R., Huggett, M. T., Ikeura, T., Jais, B., Jang, J. Y., Jang, K. T., Jung, W., Kang, C. M., Kang, H., Keane, M. G., Kim, M. H., Kim, S. W., Kimura, W., Kopchak, K. V., L\ue9vy, P., Lee, L. S., Lee, W. J., Lennon, A. M., Leong, R. W., Maggino, L., Malleo, G., Manfredi, R., Marchegiani, G., Matsumoto, I., Messina, O., Milanetto, Anna Caterina, Moon, J. H., Moran, R., Morana, G., Napoleon, B., Neoptolemos, J., Oh, D., Okazaki, K., Oppong, K. W., Osvaldt, A., Oua\uefssi, M., Pavey, D., Pereira, S. P., Pererva, L., Petrone, M. C., Rebours, V., Ricci, C., Rios Vives, M. A., Salvia, R., Sastre, B., Segersvard, R., Shinzeki, M., Song, D. H., Song, S. Y., Spandre, M., Sperti, Cosimo, Tang, J., Urman Fernandez, J. M., Vaquero, E. C., Wang, H., Wolfgang, C., Zaheer, A., Zerbi, A.   +87 more
core   +2 more sources

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Prognostic Enigma of Pancreatic Solid Pseudopapillary Neoplasm: A Single-Center Experience of 63 Patients [PDF]

, 2021
Xinbo Wang, Daojun Zhu, Wei Bao, Min Li, Sizhen Wang, Rongxi Shen   +5 more
openalex   +1 more source